• NeuroSense Therapeutics will present at the NEALS Consortium annual meeting on Oct. 30, 2026, in Clearwater, Florida.
• Scheduled for 11:25 a.m. Eastern Time, the presentation will cover clinical and biomarker findings from the PARADIGM Phase 2b program.
• The findings are shaping PARAGON, the planned Phase 3 study of PrimeC in ALS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610291130PR_NEWS_USPR_____LN84693) on October 29, 2026, and is solely responsible for the information contained therein.